Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The COVID-19 pandemic has changed science journalism. Semantics aside, though, science and health care have taken a new position in the hierarchy of top news priorities.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Moderna will leverage AbCellera’s AI-powered technology to search and analyze natural immune responses in the hopes of identifying antibodies for up to six targets.
The proceeds will be used for the companies’ growth, to help develop their platforms and advance their pipelines.
Erika Cheung testified that the data manipulation happened “frequently,” in order to make the company’s lead asset look good to investors.
The mobile app, dubbed Brisa, has been designed to help patients record their disease progression regardless of condition and treatment plans.
The company announced a Phase III cardiac drug failed to meet its primary endpoint and a significant shift in its R&D efforts that have resulted in the termination of 75% of its staff.
Sanofi is shuttering Principia’s laboratories in San Francisco after its Phase III PEGASUS trial of rilzabrutinib for pemphigus failed to meet primary or key secondary endpoints.
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Centessa Pharmaceuticals and genomics testing firm Sophia Genetics have both announced plans to expand their real estate footprints in Boston.